Natco Pharma is a vertically integrated, R&D-led pharmaceutical company that develops, manufactures and markets complex finished dosage formulations (FDF) and APIs, with a strong presence in oncology and specialty generics across the US, India and multiple emerging markets; the company also invests in NCEs, cell and gene therapies to build a biotech pipeline alongside its generic business.

Q3 FY26 consolidated revenue was INR 705.4 crore with EBITDA of INR 216.8 crore and a 30.7% EBITDA margin; Q3 PAT was INR 151.3 crore and 9MFY26 PAT stands around INR 1,149.5 crore, showing NATCO Pharma has stabilized earnings despite loss of prior Revlimid tailwinds and is guiding full‑year revenue roughly around INR 4,200–4,300 crore.

Natco’s export formulations are the revenue engine, contributing nearly 60% for the quarter and 75.7% for 9MFY26, supported by strong performance from subsidiaries in Brazil, Canada, Middle East and newly acquired exposure through Adcock Ingram; this geographic diversification materially reduces single-product concentration risk and strengthens recurring revenue streams.

The company has a deep pipeline of complex ANDAs and Para‑IV opportunities in the US (30 Para IVs with >20 FTFs and 14 approvals), active semaglutide (Ozempic/Wegovy) filings for India and regulated markets, and an explicit M&A playbook targeting large acquisitions to scale international branded businesses and expand NATCO Pharma’s footprint and product mix.

NATCO Pharma has committed to biotech investments including eGenesis, NRC-2694 (Phase II approved), Cellogen, Eyestem and Stero Therapeutics, reflecting a dual strategy of near-term generics revenue plus high-risk, high-reward R&D investments that could materially change long-term growth trajectory if clinical programs succeed.